上皮源性细胞因子白细胞介素33、白细胞介素25和胸腺基质淋巴细胞生成素在特应性皮炎发病机制中的作用

doi:10.35541/cjd.20200274

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (6): 548-551.doi: 10.35541/cjd.20200274

上皮源性细胞因子白细胞介素33、白细胞介素25和胸腺基质淋巴细胞生成素在特应性皮炎发病机制中的作用

陆晓云张曾云鸥肖风丽

安徽医科大学第一附属医院皮肤科安徽医科大学皮肤病研究所，合肥 230022

收稿日期:2020-03-18 修回日期:2021-01-15 发布日期:2022-06-02
通讯作者: 肖风丽 E-mail:xiaofengli@126.com
基金资助:
国家自然科学基金（81972926）；安徽省学术和技术带头人及后备人选学术科研活动资助项目（2017D141）

Role of epithelium-derived cytokines interleukin-33, interleukin-25 and thymic stromal lymphopoietin in the pathogenesis of atopic dermatitis

Lu Xiaoyun, Zhang Zengyunou, Xiao Fengli

Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Institute of Dermatology, Anhui Medical University, Hefei 230022, China

Received:2020-03-18 Revised:2021-01-15 Published:2022-06-02
Contact: Xiao Fengli E-mail:xiaofengli@126.com
Supported by:
National Natural Science Foundation of China （81972926）; Anhui Academic and Technical Leaders and Reserves for Academic Research Activities （2017D141）

摘要/Abstract

摘要： 【摘要】表皮屏障功能缺陷及免疫改变是特应性皮炎（AD）发生发展的主要病理生理改变，而皮肤角质形成细胞在各种损伤因素作用下可释放多种炎症因子和介质，其中3种上皮源性因子白细胞介素33、白细胞介素25、胸腺基质淋巴细胞生成素被认为是皮肤或黏膜屏障Th2型免疫应答的有效诱导因子，能够激活免疫细胞，引起Th2型细胞因子分泌，增强Th2型免疫应答，参与AD的发生与发展。本文就3种上皮源性细胞因子在AD发病机制中的作用进展进行总结。

关键词: 皮炎, 特应性, 白细胞介素类, 白细胞介素33, 白细胞介素25, 胸腺基质淋巴细胞生成素

Abstract: 【Abstract】 Epidermal barrier defects and immune abnormalities are the main pathophysiological changes in the development of atopic dermatitis （AD）. Skin keratinocytes can release a variety of inflammatory factors and mediators under the treatment with various harmful factors. Three epithelium?derived cytokines interleukin （IL）-33, IL-25 and thymic stromal lymphopoietin are considered to be effective inducers of Th2 immune response in skin or mucosal barrier, which can activate immune cells, cause the secretion of Th2 cytokines, enhance the Th2 immune response, and participate in the occurrence and development of AD. This review focuses on the role of the above 3 epithelium?derived cytokines in the pathogenesis of AD.

Key words: Dermatitis, atopic, Interleukins, Interleukin-33, Interleukin-25, Thymic stromal lymphopoietin

陆晓云张曾云鸥肖风丽. 上皮源性细胞因子白细胞介素33、白细胞介素25和胸腺基质淋巴细胞生成素在特应性皮炎发病机制中的作用[J]. 中华皮肤科杂志, 2022,55(6):548-551. doi:10.35541/cjd.20200274

Lu Xiaoyun, Zhang Zengyunou, Xiao Fengli. Role of epithelium-derived cytokines interleukin-33, interleukin-25 and thymic stromal lymphopoietin in the pathogenesis of atopic dermatitis[J]. Chinese Journal of Dermatology, 2022, 55(6): 548-551.doi:10.35541/cjd.20200274

参考文献 28

［1］	Han H, Roan F, Ziegler SF. The atopic march: current insights into skin barrier dysfunction and epithelial cell⁃derived cytokines［J］. Immunol Rev, 2017,278（1）:116⁃130. doi: 10.1111/imr.12546.
［2］	Nakamura N, Tamagawa⁃Mineoka R, Yasuike R, et al. Stratum corneum interleukin⁃33 expressions correlate with the degree of lichenification and pruritus in atopic dermatitis lesions［J］. Clin Immunol, 2019,201:1⁃3. doi: 10.1016/j.clim.2019.02.006.
［3］	Saluja R, Ketelaar ME, Hawro T, et al. The role of the IL⁃33/IL⁃1RL1 axis in mast cell and basophil activation in allergic disorders［J］. Mol Immunol, 2015,63（1）:80⁃85. doi: 10.1016/j.molimm.2014.06.018.
［4］	Rizzo JM, Oyelakin A, Min S, et al. ΔNp63 regulates IL⁃33 and IL⁃31 signaling in atopic dermatitis［J］. Cell Death Differ, 2016,23（6）:1073⁃1085. doi: 10.1038/cdd.2015.162.
［5］	Nygaard U, Hvid M, Johansen C, et al. TSLP, IL⁃31, IL⁃33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2016, 30（11）:1930⁃1938. doi: 10.1111/jdv.13679.
［6］	Ryffel B, Alves⁃Filho JC. ILC2s and basophils team up to orchestrate IL⁃33⁃induced atopic dermatitis［J］. J Invest Dermatol, 2019,139（10）:2077⁃2079. doi: 10.1016/j.jid.2019.06. 118.
［7］	Salimi M, Barlow JL, Saunders SP, et al. A role for IL⁃25 and IL⁃33⁃driven type⁃2 innate lymphoid cells in atopic dermatitis［J］. J Exp Med, 2013,210（13）:2939⁃2950. doi: 10.1084/jem.20130351.
［8］	Li C, Maillet I, Mackowiak C, et al. Experimental atopic dermatitis depends on IL⁃33R signaling via MyD88 in dendritic cells［J］. Cell Death Dis, 2017,8（4）:e2735. doi: 10.1038/cddis. 2017.90.
［9］	Nygaard U, van den Bogaard EH, Niehues H, et al. The "Alarmins" HMBG1 and IL⁃33 downregulate structural skin barrier proteins and impair epidermal growth［J］. Acta Derm Venereol, 2017,97（3）:305⁃312. doi: 10.2340/00015555⁃2552.
［10］	Ryu WI, Lee H, Bae HC, et al. IL⁃33 down⁃regulates filaggrin expression by inducing STAT3 and ERK phosphorylation in human keratinocytes［J］. J Dermatol Sci, 2016,82（2）:131⁃134. doi: 10.1016/j.jdermsci.2016.01.011.
［11］	Peng G, Mu Z, Cui L, et al. Anti⁃IL⁃33 antibody has a therapeutic effect in an atopic dermatitis murine model induced by 2, 4⁃dinitrochlorobenzene［J］. Inflammation, 2018,41（1）:154⁃163. doi: 10.1007/s10753⁃017⁃0673⁃7.
［12］	Chen YL, Gutowska⁃Owsiak D, Hardman CS, et al. Proof⁃of⁃concept clinical trial of etokimab shows a key role for IL⁃33 in atopic dermatitis pathogenesis［J］. Sci Transl Med, 2019,11（515）:eaax2945. doi: 10.1126/scitranslmed.aax2945.
［13］	Xu M, Dong C. IL⁃25 in allergic inflammation［J］. Immunol Rev, 2017, 278（1）:185⁃191. doi: 10.1111/imr.12558.
［14］	Nakamura N, Tamagawa⁃Mineoka R, Maruyama A, et al. Stratum corneum interleukin⁃25 expressions correlate with the degree of dry skin and acute lesions in atopic dermatitis［J］. Allergol Int, 2020,69（3）:462⁃464. doi: 10.1016/j.alit.2020.02.001.
［15］	Leonardi S, Cuppari C, Manti S, et al. Serum interleukin 17, interleukin 23, and interleukin 10 values in children with atopic eczema/dermatitis syndrome （AEDS）: association with clinical severity and phenotype［J］. Allergy Asthma Proc, 2015,36（1）:74⁃81. doi: 10.2500/aap.2015.36.3808.
［16］	Xu M, Lu H, Lee YH, et al. An interleukin⁃25⁃mediated autoregulatory circuit in keratinocytes plays a pivotal role in psoriatic skin inflammation［J］. Immunity, 2018,48（4）:787⁃798.e4. doi: 10.1016/j.immuni.2018.03.019.
［17］	Nakahara T, Kido⁃Nakahara M, Furue M. Potential role of endothelin⁃1 in atopic dermatitis［J］. Current Treatment Options in Allergy, 2019,6（2）:156⁃163. doi：10.1007/s40521⁃019⁃00206⁃1.
［18］	Senra L, Mylonas A, Kavanagh RD, et al. IL⁃17E （IL⁃25） enhances innate immune responses during skin inflammation［J］. J Invest Dermatol, 2019,139（8）:1732⁃1742. doi: 10. 1016/j.jid.2019.01.021.
［19］	Sawyer L, Fotheringham I, Wright E, et al. The comparative efficacy of brodalumab in patients with moderate⁃to⁃severe psoriasis: a systematic literature review and network meta⁃analysis［J］. J Dermatolog Treat, 2018,29（6）:557⁃568. doi: 10. 1080/09546634.2018.1427205.
［20］	Varricchi G, Pecoraro A, Marone G, et al. Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer［J］. Front Immunol, 2018,9:1595. doi: 10.3389/fimmu.2018.01595.
［21］	Wilson SR, Thé L, Batia LM, et al. The epithelial cell⁃derived atopic dermatitis cytokine TSLP activates neurons to induce itch［J］. Cell, 2013,155（2）:285⁃295. doi: 10.1016/j.cell.2013.08.057.
［22］	Kim JH, Bae HC, Ko NY, et al. Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 （STAT3） and extracellular signal⁃regulated kinase （ERK） phosphorylation in keratinocytes［J］. J Allergy Clin Immunol, 2015,136（1）:205⁃208.e9. doi: 10.1016/j.jaci.2015.04.026.
［23］	Fu X, Hong C. Osthole attenuates mouse atopic dermatitis by inhibiting thymic stromal lymphopoietin production from keratinocytes［J］. Exp Dermatol, 2019,28（5）:561⁃567. doi: 10. 1111/exd.13910.
［24］	Sawada Y, Honda T, Nakamizo S, et al. Prostaglandin E2 （PGE2）⁃EP2 signaling negatively regulates murine atopic dermatitis⁃like skin inflammation by suppressing thymic stromal lymphopoietin expression［J］. J Allergy Clin Immunol, 2019,144（5）:1265⁃1273. doi: 10.1016/j.jaci.2019.06.036.
［25］	Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti⁃thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial［J］. J Am Acad Dermatol, 2019,80（4）:1013⁃1021. doi: 10.1016/j.jaad.2018.11.059.
［26］	Zheng R, Chen FH, Gao WX, et al. The TH2⁃polarizing function of atopic interleukin 17 receptor B⁃positive dendritic cells up⁃regulated by lipopolysaccharide［J］. Ann Allergy Asthma Immunol, 2017,118（4）:474⁃482. doi: 10.1016/j.anai.2016.12.011.
［27］	Halim T, Rana B, Walker JA, et al. Tissue⁃restricted adaptive type 2 immunity is orchestrated by expression of the costimulatory molecule OX40L on group 2 innate lymphoid cells［J］. Immunity, 2018,48（6）:1195⁃1207. doi: 10.1016/j.immuni. 2018.05.003.
［28］	Van Dyken SJ, Nussbaum JC, Lee J, et al. A tissue checkpoint regulates type 2 immunity［J］. Nat Immunol, 2016,17（12）:1381⁃1387. doi: 10.1038/ni.3582.

[1]	中华医学会皮肤性病学分会特应性皮炎研究中心中华医学会皮肤性病学分会儿童学组. 【开放获取】度普利尤单抗治疗特应性皮炎专家共识[J]. 中华皮肤科杂志, 2022, 55(6): 465-470.
[2]	黄馨陈筱昀李亚萍梁兴堃张桂英周英湛意罗帅寒天廖洁月肖嵘龙海. 度普利尤单抗治疗123例特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(6): 486-493.
[3]	徐西光卢彬孙建方. 表现为特应性皮炎样皮损的X连锁无丙种球蛋白血症1例[J]. 中华皮肤科杂志, 2022, 55(6): 536-537.
[4]	孙晓丽李邻峰. 肥大细胞在变应性接触性皮炎发病中的作用进展[J]. 中华皮肤科杂志, 2022, 55(5): 449-451.
[5]	申晨陶娟. 特应性皮炎长期控制的评估演变与达标治疗[J]. 中华皮肤科杂志, 2022, 55(5): 442-445.
[6]	余愫郁天泽李巍. 自主神经在特应性皮炎免疫失调中的作用[J]. 中华皮肤科杂志, 2022, 55(4): 362-365.
[7]	覃诗纯李梦杰陆晓云肖风丽. 特应性皮炎的转录组学研究进展[J]. 中华皮肤科杂志, 2022, 55(4): 365-369.
[8]	李巍尹慧彬. 特应性皮炎的部位异质性[J]. 中华皮肤科杂志, 2022, 55(4): 349-352.
[9]	李妍李明徐薇李邻峰. 【开放获取】凯普斯泰冷敷凝胶治疗成人轻中度特应性皮炎的随机双盲对照研究[J]. 中华皮肤科杂志, 2022, 55(4): 345-348.
[10]	何素玲田歆梁景耀邵蕾李俊龙黄琼霄刘玉梅王建琴. 重度特应性皮炎患者急性期和缓解期皮肤微生态研究[J]. 中华皮肤科杂志, 2022, 55(4): 329-336.
[11]	刘擘宋晓婷廖双璐于淼栾婷婷李若瑜赵作涛. 【开放获取】巴瑞替尼治疗中重度特应性皮炎的疗效和安全性观察[J]. 中华皮肤科杂志, 2022, 55(4): 304-307.
[12]	田晶梁源申春平赵牧童汪洋王珊焦磊马琳. 儿童中重度特应性皮炎首次皮下注射度普利尤单抗短期疗效和安全性分析[J]. 中华皮肤科杂志, 2022, 55(4): 299-303.
[13]	刘擘宋晓婷李若瑜赵作涛. 【开放获取】度普利尤单抗治疗特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(4): 295-298.
[14]	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组中华医学会皮肤性病学分会儿童学组. 【开放获取】特应性皮炎湿包疗法临床应用专家共识[J]. 中华皮肤科杂志, 2022, 55(4): 289-294.
[15]	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组中华医学会皮肤性病学分会儿童学组中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识[J]. 中华皮肤科杂志, 2022, 55(4): 281-288.

上皮源性细胞因子白细胞介素33、白细胞介素25和胸腺基质淋巴细胞生成素在特应性皮炎发病机制中的作用

Role of epithelium-derived cytokines interleukin-33, interleukin-25 and thymic stromal lymphopoietin in the pathogenesis of atopic dermatitis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

Metrics

本文评价

推荐阅读 10